The stock of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) is a huge mover today! About 367,990 shares traded hands or 172.45% up from the average. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) has declined 0.37% since April 18, 2016 and is downtrending. It has underperformed by 4.80% the S&P500.
The move comes after 7 months negative chart setup for the $28.98M company. It was reported on Nov, 18 by Barchart.com. We have $4.19 PT which if reached, will make NASDAQ:CYCC worth $2.90 million less.
According to Zacks Investment Research, “CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.”
Insitutional Activity: The institutional sentiment decreased to 0 in 2016 Q2. Its down 0.09, from 0.09 in 2016Q1. The ratio dropped, as 23 funds sold all Cyclacel Pharmaceuticals Inc shares owned while 0 reduced positions. 2 funds bought stakes while 0 increased positions. They now own 13,631 shares or 99.80% less from 6.70 million shares in 2016Q1.
Baker Bros Advsr L P accumulated 0% or 13,253 shares. The New York-based Tower Research Limited Liability (Trc) has invested 0% in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC).
More recent Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on September 11, 2009. Also Investorplace.com published the news titled: “Cyclacel Pharmaceuticals Inc (CYCC): Don’t Believe the Hype” on August 22, 2016. Seekingalpha.com‘s news article titled: “Cyclacel Pharmaceuticals, Inc.’s (CYCC) CEO Spiro Rombotis on Q2 2016 Results …” with publication date: August 10, 2016 was also an interesting one.
CYCC Company Profile
Cyclacel Pharmaceuticals, Inc., incorporated on January 5, 1996, operates in the field of cell cycle biology. The Firm has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. The Company’s family of anticancer drugs acts on the cell cycle.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.